JP2019500848A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019500848A5 JP2019500848A5 JP2018520406A JP2018520406A JP2019500848A5 JP 2019500848 A5 JP2019500848 A5 JP 2019500848A5 JP 2018520406 A JP2018520406 A JP 2018520406A JP 2018520406 A JP2018520406 A JP 2018520406A JP 2019500848 A5 JP2019500848 A5 JP 2019500848A5
- Authority
- JP
- Japan
- Prior art keywords
- tcr
- abtcr
- domain
- tcr subunit
- chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 71
- 108091007433 antigens Proteins 0.000 claims description 71
- 102000036639 antigens Human genes 0.000 claims description 71
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 65
- 210000004027 cell Anatomy 0.000 claims description 50
- 229920001184 polypeptide Polymers 0.000 claims description 34
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 34
- 239000012636 effector Substances 0.000 claims description 32
- 150000007523 nucleic acids Chemical class 0.000 claims description 20
- 239000012634 fragment Substances 0.000 claims description 14
- 108091008874 T cell receptors Proteins 0.000 claims description 11
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 11
- 230000011664 signaling Effects 0.000 claims description 9
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 2
- 101000621309 Homo sapiens Wilms tumor protein Proteins 0.000 claims description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 2
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 claims description 2
- 101710123134 Ice-binding protein Proteins 0.000 claims description 2
- 101710082837 Ice-structuring protein Proteins 0.000 claims description 2
- 102000036673 PRAME Human genes 0.000 claims description 2
- 108060006580 PRAME Proteins 0.000 claims description 2
- 101710107540 Type-2 ice-structuring protein Proteins 0.000 claims description 2
- 229940072221 immunoglobulins Drugs 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 3
- 238000000034 method Methods 0.000 description 27
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 108010075254 C-Peptide Proteins 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 3
- 101710160107 Outer membrane protein A Proteins 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 description 2
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 241001502974 Human gammaherpesvirus 8 Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 230000004068 intracellular signaling Effects 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 1
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 description 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 102100031507 Fc receptor-like protein 5 Human genes 0.000 description 1
- 101150032879 Fcrl5 gene Proteins 0.000 description 1
- 102100021197 G-protein coupled receptor family C group 5 member D Human genes 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101001040713 Homo sapiens G-protein coupled receptor family C group 5 member D Proteins 0.000 description 1
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 description 1
- 101001103033 Homo sapiens Tyrosine-protein kinase transmembrane receptor ROR2 Proteins 0.000 description 1
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102100039616 Tyrosine-protein kinase transmembrane receptor ROR2 Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021204862A JP2022050431A (ja) | 2015-10-23 | 2021-12-17 | 抗体／ｔ細胞受容体キメラ構築物およびその使用 |
| JP2024015749A JP2024062997A (ja) | 2015-10-23 | 2024-02-05 | 抗体／ｔ細胞受容体キメラ構築物およびその使用 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562245944P | 2015-10-23 | 2015-10-23 | |
| US62/245,944 | 2015-10-23 | ||
| US201662304918P | 2016-03-07 | 2016-03-07 | |
| US62/304,918 | 2016-03-07 | ||
| US201662345649P | 2016-06-03 | 2016-06-03 | |
| US62/345,649 | 2016-06-03 | ||
| US201662369694P | 2016-08-01 | 2016-08-01 | |
| US62/369,694 | 2016-08-01 | ||
| PCT/US2016/058305 WO2017070608A1 (en) | 2015-10-23 | 2016-10-21 | Antibody/t-cell receptor chimeric constructs and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021204862A Division JP2022050431A (ja) | 2015-10-23 | 2021-12-17 | 抗体／ｔ細胞受容体キメラ構築物およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019500848A JP2019500848A (ja) | 2019-01-17 |
| JP2019500848A5 true JP2019500848A5 (enExample) | 2019-12-05 |
| JP7316042B2 JP7316042B2 (ja) | 2023-07-27 |
Family
ID=58558140
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018520406A Active JP7316042B2 (ja) | 2015-10-23 | 2016-10-21 | 抗体／ｔ細胞受容体キメラ構築物およびその使用 |
| JP2021204862A Pending JP2022050431A (ja) | 2015-10-23 | 2021-12-17 | 抗体／ｔ細胞受容体キメラ構築物およびその使用 |
| JP2024015749A Pending JP2024062997A (ja) | 2015-10-23 | 2024-02-05 | 抗体／ｔ細胞受容体キメラ構築物およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021204862A Pending JP2022050431A (ja) | 2015-10-23 | 2021-12-17 | 抗体／ｔ細胞受容体キメラ構築物およびその使用 |
| JP2024015749A Pending JP2024062997A (ja) | 2015-10-23 | 2024-02-05 | 抗体／ｔ細胞受容体キメラ構築物およびその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (7) | US11421013B2 (enExample) |
| EP (2) | EP3365364B1 (enExample) |
| JP (3) | JP7316042B2 (enExample) |
| KR (2) | KR20250036959A (enExample) |
| CN (4) | CN116059316A (enExample) |
| AU (2) | AU2016342041B2 (enExample) |
| CA (1) | CA3001137A1 (enExample) |
| DK (1) | DK3365364T5 (enExample) |
| ES (1) | ES2979220T3 (enExample) |
| IL (3) | IL258405B (enExample) |
| MX (1) | MX2018004721A (enExample) |
| MY (1) | MY194628A (enExample) |
| PH (1) | PH12018500861A1 (enExample) |
| RU (1) | RU2767209C2 (enExample) |
| SG (3) | SG10201913245UA (enExample) |
| TW (2) | TWI780031B (enExample) |
| WO (1) | WO2017070608A1 (enExample) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113968912B (zh) | 2014-12-05 | 2025-05-16 | 纪念斯隆-凯特琳癌症中心 | 靶向g-蛋白偶联受体的嵌合抗原受体及其用途 |
| KR102602417B1 (ko) | 2014-12-05 | 2023-11-16 | 메모리얼 슬로안 케터링 캔서 센터 | G-단백질 커플화 수용체를 표적화하는 항체 및 이의 사용 방법 |
| BR112017024757A2 (pt) | 2015-05-18 | 2018-11-13 | TCR2 Therapeutics Inc. | composições e métodos para reprogramação de tcr utilizando proteínas de fusão |
| CN116059316A (zh) * | 2015-10-23 | 2023-05-05 | 优瑞科生物技术公司 | 抗体/t细胞受体嵌合构建体及其用途 |
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| WO2017189964A2 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| CA3039406A1 (en) | 2016-09-19 | 2018-03-22 | University Of Southern California | Non-radioactive cytotoxicity assays |
| JP7685735B2 (ja) * | 2016-12-02 | 2025-05-30 | アンヘレス セラピューティクス インコーポレイテッド | 合成免疫受容体およびその使用方法 |
| AU2018258045B2 (en) * | 2017-04-26 | 2024-02-29 | Eureka Therapeutics, Inc. | Chimeric antibody/T-cell receptor constructs and uses thereof |
| IL270138B2 (en) | 2017-04-26 | 2025-08-01 | Eureka Therapeutics Inc | Structures that specifically recognize glypican 3 and their uses |
| PT3428194T (pt) * | 2017-07-14 | 2021-11-18 | Immatics Biotechnologies Gmbh | Molécula de polipéptido com especificidade dupla melhorada |
| EP3679065A4 (en) | 2017-09-06 | 2021-05-19 | California Institute of Technology | SIGNALING AND ANTIGEN-PRESENTING BIFUNCTIONAL RECEPTORS (SABR) |
| WO2019057124A1 (en) | 2017-09-22 | 2019-03-28 | Wuxi Biologics (Shanghai) Co., Ltd. | NEW BISPECIFIC CD3 / CD19 POLYPEPTIDE COMPLEXES |
| MA50188A (fr) * | 2017-09-22 | 2021-06-02 | Wuxi Biologics Ireland Ltd | Nouveaux complexes polypeptidiques bispécifiques |
| BR112020005938A2 (pt) * | 2017-09-27 | 2020-11-17 | University Of Southern California | célula imune ou população de células imunes da mesma, célula efetora imune ou célula-tronco, célula que apresenta antígeno, polinucleotídeo recombinante, vetor, composição que compreende uma célula imune efetora ou uma célula-tronco, métodos para produzir uma célula efetora imune que expressa receptor imune de ocorrência não natural, para gerar uma população de células manipuladas por rna, para fornecer imunidade antidoença em um indivíduo, para tratar ou prevenir uma doença associada à expressão de um antígeno, e, uso |
| GB201718088D0 (en) * | 2017-11-01 | 2017-12-13 | Autolus Ltd | Vectors |
| MX2020004572A (es) | 2017-11-01 | 2020-10-07 | Juno Therapeutics Inc | Receptores de antigenos quimericos especificos para el antigeno de maduracion de celulas b y polinucleotidos que codifican los mismos. |
| CN109971715A (zh) * | 2017-12-28 | 2019-07-05 | 深圳华大生命科学研究院 | 一种扩增特异性car-t细胞的培养方法 |
| EP3747456A4 (en) * | 2018-01-31 | 2021-12-01 | Tohoku University | PROCESS FOR REGULATING THE EXPRESSION OF THE SPECIFIC MHC OF AN ANTIGEN |
| GB201801920D0 (en) * | 2018-02-06 | 2018-03-21 | Autolus Ltd | Polypeptides and methods |
| AU2019216982B2 (en) * | 2018-02-11 | 2024-07-04 | Memorial Sloan-Kettering Cancer Center | Non-HLA restricted T cell receptors and uses thereof |
| SG11202007697VA (en) | 2018-02-15 | 2020-09-29 | Memorial Sloan Kettering Cancer Center | Foxp3 targeting agent compositions and methods of use for adoptive cell therapy |
| AU2019231315A1 (en) | 2018-03-09 | 2020-09-17 | Vivasor, Inc. | Dimeric antigen receptors (DAR) |
| KR102943105B1 (ko) * | 2018-03-23 | 2026-03-24 | 가비쉬-가릴리 바이오 어플리케이션스 리미티드. | 막-결합된 IL-10을 발현하는 유전자 리프로그래밍된 Treg |
| CA3095595A1 (en) * | 2018-03-30 | 2019-10-03 | Eureka Therapeutics, Inc. | Constructs targeting cd22 and uses thereof |
| CN110407927B (zh) * | 2018-04-26 | 2022-09-09 | 香雪生命科学技术（广东）有限公司 | 一种识别afp抗原的tcr |
| CA3101510A1 (en) * | 2018-06-01 | 2019-12-05 | University Of Southern California | Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy |
| CA3103936A1 (en) | 2018-06-18 | 2019-12-26 | Eureka Therapeutics, Inc. | Constructs targeting prostate-specific membrane antigen (psma) and uses thereof |
| AU2019315226B2 (en) * | 2018-08-03 | 2025-09-18 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing two antigen-binding domains that are linked to each other |
| CN110818802B (zh) * | 2018-08-08 | 2022-02-08 | 华夏英泰（北京）生物技术有限公司 | 一种嵌合t细胞受体star及其应用 |
| CN113260634A (zh) * | 2018-09-28 | 2021-08-13 | 中外制药株式会社 | 包含改变的抗体可变区的抗原结合分子 |
| SG11202104188VA (en) | 2018-11-01 | 2021-05-28 | Juno Therapeutics Inc | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
| JP7627216B2 (ja) | 2018-11-16 | 2025-02-05 | メモリアル スローン ケタリング キャンサー センター | ムチン－１６に対する抗体およびそれを使用する方法 |
| US20220033848A1 (en) * | 2018-11-19 | 2022-02-03 | Board Of Regents, The University Of Texas System | A modular, polycistronic vector for car and tcr transduction |
| US12325734B2 (en) | 2019-01-15 | 2025-06-10 | Altor Bioscience Llc | Human immunodeficiency virus-specific T cell receptors |
| CN110006724B (zh) * | 2019-04-17 | 2021-06-04 | 郑州安图生物工程股份有限公司 | 采用巴氏和革兰氏染色方法检测滴虫用试剂 |
| DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| EP4010697A4 (en) * | 2019-08-05 | 2022-10-12 | Charles River Laboratories, Inc. | ANTIGEN-BINDING MOLECULES AND THEIR SCREENING METHODS |
| WO2021030153A2 (en) * | 2019-08-09 | 2021-02-18 | A2 Biotherapeutics, Inc. | Engineered t cell receptors and uses thereof |
| JP2022546577A (ja) * | 2019-09-05 | 2022-11-04 | ソレント・セラピューティクス・インコーポレイテッド | Ｂｃｍａと結合する二量体抗原受容体（ｄａｒ） |
| AU2020344628A1 (en) * | 2019-09-12 | 2022-04-07 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| CN115335399A (zh) | 2019-12-06 | 2022-11-11 | 朱诺治疗学股份有限公司 | 针对gprc5d靶结合结构域的抗独特型抗体以及相关组合物和方法 |
| JP7614659B2 (ja) * | 2019-12-30 | 2025-01-16 | ブリスター イムノテック リミテッド | 強化されたｔ細胞受容体ｓｔａｒ及びその用途 |
| CN115427084A (zh) * | 2020-01-10 | 2022-12-02 | T细胞受体治疗公司 | 用于自身免疫调节的组合物和方法 |
| CN111320703A (zh) * | 2020-03-11 | 2020-06-23 | 北京双赢科创生物科技有限公司 | 靶向cd22的嵌合抗原受体及其应用 |
| EP4592310A2 (en) | 2020-03-16 | 2025-07-30 | Angeles Therapeutics, Inc. | Novel antigen binding domains and synthetic antigen receptors incorporating the same |
| MX2022011673A (es) | 2020-03-20 | 2022-12-13 | Lyell Immunopharma Inc | Nuevos marcadores de superficie celular recombinantes. |
| US12365871B2 (en) | 2020-04-28 | 2025-07-22 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| CA3187163A1 (en) * | 2020-05-07 | 2021-11-11 | China Immunotech (Beijing) Biotechnology Co., Ltd | Improved t cell receptor-costimulatory molecule chimera |
| JP7591772B2 (ja) * | 2020-05-25 | 2024-11-29 | ブリスター イムノテック リミテッド | 強化された合成ｔ細胞受容体及び抗原受容体 |
| EP4281473A4 (en) * | 2021-01-19 | 2024-12-18 | Wuxi Biologics Ireland Limited | POLYPEPTIDE COMPLEXES WITH ENHANCED STABILITY AND EXPRESSION |
| TW202239768A (zh) | 2021-01-27 | 2022-10-16 | 美商萊爾免疫藥物股份有限公司 | 改良之免疫細胞療法 |
| WO2022182915A1 (en) | 2021-02-25 | 2022-09-01 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| US20250326855A1 (en) | 2021-03-05 | 2025-10-23 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
| BR112023022765A2 (pt) | 2021-05-05 | 2024-01-02 | Immatics Biotechnologies Gmbh | Proteínas de ligação ao antígeno que ligam especificamente o prame |
| BR112023022975A2 (pt) | 2021-05-05 | 2024-01-23 | Immatics Biotechnologies Gmbh | Polipeptídeos de ligação ao antígeno bma031 melhorados |
| EP4377336A4 (en) * | 2021-07-29 | 2025-07-16 | Nantcell Inc | MODIFIED T CELL RECEPTORS FOR THE PREVENTION AND TREATMENT OF VIRAL INFECTIONS AND CANCER |
| US20250101126A1 (en) | 2021-08-05 | 2025-03-27 | Go Therapeutics, Inc. | Anti-glyco-muc4 antibodies and their uses |
| AU2022339819A1 (en) | 2021-09-03 | 2024-04-11 | Go Therapeutics, Inc. | Anti-glyco-lamp1 antibodies and their uses |
| WO2023034569A1 (en) | 2021-09-03 | 2023-03-09 | Go Therapeutics, Inc. | Anti-glyco-cmet antibodies and their uses |
| US20250228939A1 (en) | 2021-10-21 | 2025-07-17 | Lyell Immunopharma, Inc. | Enhanced immune cell therapy |
| WO2023077026A1 (en) | 2021-10-28 | 2023-05-04 | Lyell Immunopharma, Inc. | Methods for culturing cells expressing ror1-binding protein |
| US20230313138A1 (en) | 2021-10-28 | 2023-10-05 | Lyell Immunopharma, Inc. | Methods for culturing cells expressing c-jun |
| CA3234825A1 (en) | 2021-10-28 | 2023-05-04 | Lyell Immunopharma, Inc. | Methods of generating cells |
| WO2023133540A1 (en) | 2022-01-07 | 2023-07-13 | Lyell Immunopharma, Inc. | Il-12 affinity variants |
| CN116063457A (zh) * | 2022-04-27 | 2023-05-05 | 恒瑞源正(广州)生物科技有限公司 | Mage-a1特异性t细胞受体及其用途 |
| WO2024020429A1 (en) | 2022-07-22 | 2024-01-25 | Lyell Immunopharma, Inc. | Immune cell therapy |
| WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
| WO2024062138A1 (en) | 2022-09-23 | 2024-03-28 | Mnemo Therapeutics | Immune cells comprising a modified suv39h1 gene |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024100136A1 (en) * | 2022-11-08 | 2024-05-16 | Gadeta B.V. | Novel method for obtaining gamma t-cell (or delta t-cell) receptor chains (or gamma delta t-cell receptors) or fragments thereof that mediate an anti-tumour or an anti-infective response |
| WO2024103251A1 (zh) * | 2022-11-15 | 2024-05-23 | 原启生物科技(上海)有限责任公司 | 抗afp/hla02 tcr样抗体及其用途 |
| WO2024148337A1 (en) * | 2023-01-05 | 2024-07-11 | Angeles Therapeutics, Inc. | Methods and compositions for gene transduction and to control the activity of synthetic and immune receptors |
| WO2024148369A1 (en) | 2023-01-07 | 2024-07-11 | Lyell Immunopharma, Inc. | Targeted il-12 affinity variants |
| WO2024182539A1 (en) | 2023-02-28 | 2024-09-06 | Lyell Immunopharma, Inc. | Methods of culturing reprogrammed cells |
| KR20260030127A (ko) | 2023-06-27 | 2026-03-05 | 라이엘 이뮤노파마, 인크. | Il-12 안정성 변이체 |
| WO2025024559A1 (en) | 2023-07-24 | 2025-01-30 | Strand Therapeutics Inc. | Rna-based synthetic circuit for producing engineered immune cells for an extracorporeal cell therapy |
| WO2025047925A1 (ja) * | 2023-08-31 | 2025-03-06 | 国立大学法人三重大学 | ハイブリッドｔ細胞受容体 |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
| WO2026006604A1 (en) | 2024-06-26 | 2026-01-02 | Lyell Immunopharma, Inc. | Feeder cell replacement |
Family Cites Families (124)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3753357A (en) | 1970-12-14 | 1973-08-21 | Ovitron Res Corp | Method and apparatus for the preservation of cells and tissues |
| US4199022A (en) | 1978-12-08 | 1980-04-22 | The United States Of America As Represented By The Department Of Energy | Method of freezing living cells and tissues with improved subsequent survival |
| US4559298A (en) | 1982-11-23 | 1985-12-17 | American National Red Cross | Cryopreservation of biological materials in a non-frozen or vitreous state |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5906936A (en) | 1988-05-04 | 1999-05-25 | Yeda Research And Development Co. Ltd. | Endowing lymphocytes with antibody specificity |
| IL86278A (en) | 1988-05-04 | 2003-06-24 | Yeda Res & Dev | Endowing cells with antibody specificity using chimeric t cell receptor |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US8211422B2 (en) | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| US5585358A (en) | 1993-07-06 | 1996-12-17 | Yissum Research Development Corporation Of The Hebrew University Of Jerusalem | Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| EP0835306A1 (en) | 1995-06-30 | 1998-04-15 | Kobenhavns Universitet | Recombinant antibodies from a phage display library, directed against a peptide-mhc complex |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| AU757961B2 (en) * | 1998-09-30 | 2003-03-13 | Sankyo Company Limited | Anti-Fas antibodies |
| EP1235842A4 (en) | 1999-10-15 | 2003-04-23 | Univ Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| EP1240319A1 (en) | 1999-12-15 | 2002-09-18 | Genentech, Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| BR0108545A (pt) | 2000-02-24 | 2004-06-29 | Xcyte Therapies Inc | Estimulação e concentração simultâneas das células |
| AU2001247616B2 (en) | 2000-04-11 | 2007-06-14 | Genentech, Inc. | Multivalent antibodies and uses therefor |
| AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
| AU2001297703B2 (en) | 2000-11-07 | 2006-10-19 | City Of Hope | CD19-specific redirected immune cells |
| US7521053B2 (en) * | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| DE60226641D1 (de) | 2001-12-03 | 2008-06-26 | Amgen Fremont Inc | Antikörperkategorisierung auf der grundlage von bindungseigenschaften |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| EP1485075A4 (en) * | 2002-02-20 | 2006-04-26 | Dyax Corp | MHC-PEPTIDE COMPLEX BINDING LIGANDS |
| PT2332989E (pt) | 2002-05-22 | 2015-08-05 | Esbatech Alcon Biomed Res Unit | Estruturas de imunoglobulina que demonstram estabilidade aumentada no ambiente intracelular e métodos de identificação das mesmas |
| CA2488441C (en) | 2002-06-03 | 2015-01-27 | Genentech, Inc. | Synthetic antibody phage libraries |
| US20050079574A1 (en) | 2003-01-16 | 2005-04-14 | Genentech, Inc. | Synthetic antibody phage libraries |
| DK1629011T3 (da) | 2003-05-31 | 2010-05-03 | Micromet Ag | Humane anti-humane-DC3-bindingsmolekyler |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| AU2005247950B2 (en) | 2004-05-27 | 2012-02-02 | Receptor Logic, Inc. | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| CN101198698B (zh) | 2005-03-31 | 2014-03-19 | 中外制药株式会社 | 通过调节多肽缔合制备多肽的方法 |
| KR20080031001A (ko) * | 2005-06-02 | 2008-04-07 | 아스트라제네카 아베 | Ｃｄ20에 대한 항체 및 그의 용도 |
| EP1899379B1 (en) | 2005-06-20 | 2018-04-11 | E. R. Squibb & Sons, L.L.C. | Cd19 antibodies and their uses |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP1945246A4 (en) | 2005-09-22 | 2009-03-11 | Irun R Cohen | IMMUNOGENIC FRAGMENTS OF CONSTANT DOMAINS OF THE T CELL RECEPTOR AND PEPTIDES DERIVED THEREFROM |
| EP1957531B1 (en) | 2005-11-07 | 2016-04-13 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
| WO2007064919A2 (en) | 2005-12-02 | 2007-06-07 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| EP2013236B1 (en) | 2006-04-28 | 2015-06-17 | Delenex Therapeutics AG | Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk |
| AU2007248019B2 (en) * | 2006-05-03 | 2012-10-11 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Chimeric T cell receptors and related materials and methods of use |
| CA2651567A1 (en) | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
| AU2007254859A1 (en) | 2006-06-01 | 2007-12-13 | Receptor Logic, Ltd | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| JP5401314B2 (ja) | 2006-09-08 | 2014-01-29 | メディミューン，エルエルシー | ヒト化抗ｃｄ１９抗体ならびに癌、移植および自己免疫疾患の治療におけるその使用 |
| DK2155789T3 (da) | 2007-05-01 | 2013-10-21 | Res Dev Foundation | Immunoglobulin-Fc-biblioteker |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| UA121093C2 (uk) | 2008-06-25 | 2020-04-10 | Атенікс Корпорейшн | Конструкція, яка містить токсиген, що кодує пестицидний білок, і спосіб її застосування для знищення напівтвердокрилих шкідників |
| PE20100362A1 (es) | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
| WO2010059543A1 (en) | 2008-11-20 | 2010-05-27 | Merck Sharp & Dohme Corp. | Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use |
| US20100153133A1 (en) | 2008-12-16 | 2010-06-17 | International Business Machines Corporation | Generating Never-Event Cohorts from Patient Care Data |
| WO2010091637A1 (en) | 2009-02-10 | 2010-08-19 | Shenogen Pharma Group Ltd. | Antibodies and methods for treating estrogen receptor-associated diseases |
| EP2258719A1 (en) | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
| WO2011012720A2 (en) | 2009-07-30 | 2011-02-03 | Helmholtz-Zentrum für Infektionsforschung GmbH | Compositions for generating an antigen specific immune response |
| AU2010309438A1 (en) | 2009-10-22 | 2012-06-07 | Ricardo J. Moro | Peptides that bind the alpha-fetoprotein (AFP) receptor and uses thereof |
| US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| US9169328B2 (en) | 2010-03-26 | 2015-10-27 | Memorial Sloan Kettering Cancer Center | Antibodies to MUC16 and methods of use thereof |
| WO2012050374A2 (en) | 2010-10-13 | 2012-04-19 | Innocell, Inc. | Immunotherapy for solid tumors |
| AU2012236068A1 (en) | 2011-04-01 | 2013-10-17 | Eureka Therapeutics, Inc. | T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2 |
| US10239952B2 (en) | 2011-04-01 | 2019-03-26 | Memorial Sloan Kettering Cancer Center | Anti-WT1/HLA bi-specific antibody |
| UY34317A (es) * | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
| US20130280220A1 (en) | 2012-04-20 | 2013-10-24 | Nabil Ahmed | Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
| EP2843051B1 (en) | 2012-04-23 | 2018-06-06 | GeneFrontier Corporation | Anti-human cd69 antibody, and use thereof for medical purposes |
| CN103319595B (zh) | 2012-07-04 | 2016-12-28 | 中国药科大学 | 抗人afp单链抗体以及融合抗原肽的制备方法和应用 |
| AU2013289971A1 (en) | 2012-07-13 | 2015-01-22 | The Trustees Of The University Of Pennsylvania | Enhancing activity of CAR T cells by co-introducing a bispecific antibody |
| WO2014014796A1 (en) * | 2012-07-18 | 2014-01-23 | Eli Lilly And Company | Multi-specific igg-(fab)2 constructs containing t-cell receptor constant domains |
| ES2714523T3 (es) | 2012-09-04 | 2019-05-28 | Cellectis | Receptor quimérico de antígenos multicatenario y usos del mismo |
| SG11201502598SA (en) | 2012-10-02 | 2015-05-28 | Sloan Kettering Inst Cancer | Compositions and methods for immunotherapy |
| CN102993305B (zh) | 2012-11-16 | 2015-05-13 | 上海赛伦生物技术有限公司 | 人源抗人表皮生长因子受体抗体及其编码基因与应用 |
| US20160000893A1 (en) | 2012-12-13 | 2016-01-07 | University Of Virginia Patent Foundation | Target peptides for ovarian cancer therapy and diagnostics |
| CN103965362B (zh) | 2013-02-06 | 2019-02-01 | 上海细胞治疗集团有限公司 | 一种可使t细胞趋向肿瘤部位的嵌合趋化因子受体 |
| WO2014123165A1 (ja) | 2013-02-06 | 2014-08-14 | 旭硝子株式会社 | 透明面材およびそれを用いた表示装置 |
| US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| EP2975942B1 (en) * | 2013-03-21 | 2018-08-08 | Sangamo Therapeutics, Inc. | Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases |
| KR101536668B1 (ko) | 2013-06-18 | 2015-07-15 | 사회복지법인 삼성생명공익재단 | 인간 및 마우스 c-Met에 교차결합하는 항체 및 그의 용도 |
| GB201313377D0 (en) | 2013-07-26 | 2013-09-11 | Adaptimmune Ltd | T cell receptors |
| WO2015063069A1 (en) | 2013-10-28 | 2015-05-07 | Benjamin Felder | Chimeric antigen receptors with antigen binding domains derived from gamma delta t cell receptors |
| ES2742224T3 (es) | 2013-11-07 | 2020-02-13 | Memorial Sloan Kettering Cancer Center | Anticuerpos biespecíficos anti-WT1/HLA |
| CN104087592B (zh) | 2014-05-13 | 2016-01-27 | 天津医科大学总医院 | Afp158-166特异性tcr基因及其转基因t细胞及体外增殖方法及用途 |
| EP3872094A3 (en) | 2014-12-05 | 2021-12-08 | Memorial Sloan Kettering Cancer Center | Antibodies targeting b-cell maturation antigen and methods of use |
| KR102602417B1 (ko) | 2014-12-05 | 2023-11-16 | 메모리얼 슬로안 케터링 캔서 센터 | G-단백질 커플화 수용체를 표적화하는 항체 및 이의 사용 방법 |
| WO2016142768A1 (en) | 2015-03-10 | 2016-09-15 | Eureka Therapeutics, Inc. | Ror2 antibody |
| CA2979976A1 (en) | 2015-03-17 | 2016-09-22 | Memorial Sloan Kettering Cancer Center | Anti-muc16 antibodies and uses thereof |
| WO2016161390A1 (en) | 2015-04-03 | 2016-10-06 | Eureka Therapeutics, Inc. | Constructs targeting afp peptide/mhc complexes and uses thereof |
| RU2017142716A (ru) | 2015-05-08 | 2019-06-10 | Еурека Терапьютикс, Инк. | Конструкции, направленные на комплексы пептида hpv16-e7/мнс, и виды их использования |
| BR112017024757A2 (pt) | 2015-05-18 | 2018-11-13 | TCR2 Therapeutics Inc. | composições e métodos para reprogramação de tcr utilizando proteínas de fusão |
| WO2016187220A2 (en) | 2015-05-18 | 2016-11-24 | Five Prime Therapeutics, Inc. | Anti-ror1 antibodies |
| CN107921127B (zh) | 2015-05-22 | 2022-04-08 | 纪念斯隆-凯特琳癌症中心 | 对于prame肽具有特异性的t细胞受体样抗体 |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| EP3307319A4 (en) | 2015-06-09 | 2019-05-22 | Memorial Sloan Kettering Cancer Center | T CELL RECEPTOR-SIMILAR ANTIBODIES SPECIFIC TO PEPTID OF THE LATENT EBV MEMBRANE PROTEIN 2A PRESENTED BY HUMAN HLA |
| KR20180012850A (ko) | 2015-06-24 | 2018-02-06 | 유레카 쎄라퓨틱스, 인코포레이티드 | Ny-eso-1 펩티드/mhc 복합체를 표적화하는 구축물 및 그의 용도 |
| US11059880B2 (en) | 2015-06-30 | 2021-07-13 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Redirected cells with MHC chimeric receptors and methods of use in immunotherapy |
| TW201708260A (zh) | 2015-07-22 | 2017-03-01 | 優瑞卡醫療公司 | 靶向ｐｓａ胜肽／ｍｈｃ複合體之構築體及其用途 |
| MX2018004515A (es) | 2015-10-13 | 2019-04-15 | Eureka Therapeutics Inc | Agentes de anticuerpo especificos para cd19 humano y usos de los mismos. |
| CN116059316A (zh) | 2015-10-23 | 2023-05-05 | 优瑞科生物技术公司 | 抗体/t细胞受体嵌合构建体及其用途 |
| CN105331585A (zh) | 2015-11-13 | 2016-02-17 | 科济生物医药（上海）有限公司 | 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞 |
| CN109071654B (zh) | 2015-12-04 | 2022-09-23 | 纪念斯隆-凯特琳癌症中心 | 靶向Fc受体样5的抗体及使用方法 |
| WO2017124001A2 (en) | 2016-01-14 | 2017-07-20 | Memorial Sloan-Kettering Cancer Center | T cell receptor-like antibodies specific for foxp3-derived peptides |
| WO2018057967A2 (en) | 2016-09-23 | 2018-03-29 | Eureka Therapeutics, Inc. | Constructs targeting hiv peptide/mhc complexes and uses thereof |
| IL270138B2 (en) | 2017-04-26 | 2025-08-01 | Eureka Therapeutics Inc | Structures that specifically recognize glypican 3 and their uses |
| CA3095595A1 (en) | 2018-03-30 | 2019-10-03 | Eureka Therapeutics, Inc. | Constructs targeting cd22 and uses thereof |
| CA3103936A1 (en) | 2018-06-18 | 2019-12-26 | Eureka Therapeutics, Inc. | Constructs targeting prostate-specific membrane antigen (psma) and uses thereof |
| JP7627216B2 (ja) | 2018-11-16 | 2025-02-05 | メモリアル スローン ケタリング キャンサー センター | ムチン－１６に対する抗体およびそれを使用する方法 |
| CN114127116A (zh) | 2019-05-08 | 2022-03-01 | 纪念斯隆凯特琳癌症中心 | 针对黏蛋白-16的人源化抗体及其使用方法 |
-
2016
- 2016-10-21 CN CN202210865517.1A patent/CN116059316A/zh active Pending
- 2016-10-21 RU RU2018118652A patent/RU2767209C2/ru active
- 2016-10-21 KR KR1020257007002A patent/KR20250036959A/ko active Pending
- 2016-10-21 CN CN201680023511.2A patent/CN107614519B/zh active Active
- 2016-10-21 IL IL258405A patent/IL258405B/en unknown
- 2016-10-21 IL IL295398A patent/IL295398B2/en unknown
- 2016-10-21 EP EP16858388.8A patent/EP3365364B1/en active Active
- 2016-10-21 CN CN202210862478.XA patent/CN115927191A/zh active Pending
- 2016-10-21 JP JP2018520406A patent/JP7316042B2/ja active Active
- 2016-10-21 US US15/769,724 patent/US11421013B2/en active Active
- 2016-10-21 SG SG10201913245UA patent/SG10201913245UA/en unknown
- 2016-10-21 SG SG10201913247XA patent/SG10201913247XA/en unknown
- 2016-10-21 IL IL314725A patent/IL314725A/en unknown
- 2016-10-21 CN CN202210861652.9A patent/CN115925973A/zh active Pending
- 2016-10-21 SG SG11201802895QA patent/SG11201802895QA/en unknown
- 2016-10-21 ES ES16858388T patent/ES2979220T3/es active Active
- 2016-10-21 MX MX2018004721A patent/MX2018004721A/es unknown
- 2016-10-21 MY MYPI2018000550A patent/MY194628A/en unknown
- 2016-10-21 WO PCT/US2016/058305 patent/WO2017070608A1/en not_active Ceased
- 2016-10-21 DK DK16858388.8T patent/DK3365364T5/da active
- 2016-10-21 KR KR1020187014004A patent/KR102777395B1/ko active Active
- 2016-10-21 CA CA3001137A patent/CA3001137A1/en active Pending
- 2016-10-21 AU AU2016342041A patent/AU2016342041B2/en active Active
- 2016-10-21 EP EP20214936.5A patent/EP3842450A1/en active Pending
- 2016-10-24 TW TW105134336A patent/TWI780031B/zh active
- 2016-10-24 TW TW111134706A patent/TWI856368B/zh active
-
2017
- 2017-12-01 US US15/829,793 patent/US10098951B2/en active Active
-
2018
- 2018-04-20 PH PH12018500861A patent/PH12018500861A1/en unknown
- 2018-09-04 US US16/121,475 patent/US10464988B2/en active Active
-
2019
- 2019-10-29 US US16/667,781 patent/US10822389B2/en active Active
-
2021
- 2021-02-22 US US17/181,913 patent/US11976105B2/en active Active
- 2021-12-17 JP JP2021204862A patent/JP2022050431A/ja active Pending
-
2022
- 2022-02-25 AU AU2022201334A patent/AU2022201334B2/en active Active
- 2022-04-08 US US17/716,667 patent/US20220348629A1/en not_active Abandoned
-
2024
- 2024-02-05 JP JP2024015749A patent/JP2024062997A/ja active Pending
-
2025
- 2025-01-30 US US19/041,816 patent/US20250361286A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018118652A (ru) | Химерные конструкции антитело/т-клеточный рецептор и их применения | |
| CN102695717B (zh) | T细胞受体 | |
| CN108135998B (zh) | 高亲合力hpv t细胞受体 | |
| JP6639233B2 (ja) | Ｍａｇｅ−ａ１を認識する高結合活性結合分子 | |
| JP2023021396A (ja) | キメラ抗原受容体 | |
| JP6985934B2 (ja) | 操作された造血幹細胞／前駆細胞及び非ｔエフェクター細胞、ならびにその使用 | |
| JP2023071729A5 (enExample) | ||
| JP2022523961A5 (enExample) | ||
| KR20190016960A (ko) | γδ T-세포 집단의 선택적 확장을 위한 방법 및 그의 조성물 | |
| US20180223255A1 (en) | Activation and Expansion of T Cells | |
| WO2018033726A1 (en) | Retroviral and lentiviral vectors | |
| JP2021524248A5 (enExample) | ||
| EP3827075A1 (en) | Nef-containing t cells and methods of producing thereof | |
| JP2021532742A5 (enExample) | ||
| KR20230013257A (ko) | 종양 미세환경의 역전을 위한 융합 단백질 및 이의 응용 | |
| JP7747724B2 (ja) | マウス定常領域を伴うｔｃｒを発現する細胞を選択的に増幅するための方法 | |
| CN110776562A (zh) | 一种识别afp抗原的t细胞受体 | |
| Lyu et al. | A novel and simple method to produce large amounts of recombinant soluble peptide/major histocompatibility complex monomers for analysis of antigen-specific human T cell receptors | |
| CA3151106A1 (en) | Tcr constructs specific for ebv-derived antigens | |
| ES2877820T3 (es) | Composiciones y métodos para la clonación rápida de receptores de células T | |
| CN112041432A (zh) | Foxp3靶向剂组合物以及用于过继细胞疗法的使用方法 | |
| CN119613563A (zh) | 编码car的核酸分子和含其的载体、car、含car的免疫细胞及其制造方法和含该细胞的医药组合物及提升细胞损伤活性的方法 | |
| CN107129537A (zh) | 抗乙型肝炎病毒的免疫反应性细胞 | |
| JP7518915B2 (ja) | Ｃｄ３融合タンパク質およびその使用 | |
| JP2021511054A5 (enExample) |